Serum AKR1A1 Levels Predict eGFR Decline Rate in African Americans with Type 2 Diabetes.

IF 3 Q1 UROLOGY & NEPHROLOGY

Kidney360 Pub Date : 2025-10-06 DOI:10.34067/KID.0000000966

Lijun Ma, Young A Choi, DengFeng Li, Moin A Saleem, Barry I Freedman

{"title":"Serum AKR1A1 Levels Predict eGFR Decline Rate in African Americans with Type 2 Diabetes.","authors":"Lijun Ma, Young A Choi, DengFeng Li, Moin A Saleem, Barry I Freedman","doi":"10.34067/KID.0000000966","DOIUrl":null,"url":null,"abstract":"Background: African Americans have disproportionately high rates of diabetic kidney disease (DKD). Identification of biomarkers predicting early DKD progression is essential to prescribe protective treatments prior to the development of irreversible histologic lesions and markedly reduced kidney function.Methods: We tested whether AKR1A1 was a marker of early DKD progression via knock-out of AKR1A1 in a human kidney proximal tubule cell line, and by measuring serum AKR1A1 concentrations in African Americans with type 2 diabetes (T2D).Results: AKR1A1 knockout cells had reduced cell viability, and the effect was aggravated by administering high dose palmitate. In addition, higher serum AKR1A1 concentrations in African Americans with T2D and preserved kidney function predicted slower decline rate in estimated glomerular filtration rate over time.Conclusions: AKR1A1 appears to play a critical role in countering toxic effects of fatty acid metabolism and may prevent rapid decline of kidney function in African Americans with T2D.","PeriodicalId":17882,"journal":{"name":"Kidney360","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney360","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34067/KID.0000000966","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: African Americans have disproportionately high rates of diabetic kidney disease (DKD). Identification of biomarkers predicting early DKD progression is essential to prescribe protective treatments prior to the development of irreversible histologic lesions and markedly reduced kidney function.

Methods: We tested whether AKR1A1 was a marker of early DKD progression via knock-out of AKR1A1 in a human kidney proximal tubule cell line, and by measuring serum AKR1A1 concentrations in African Americans with type 2 diabetes (T2D).

Results: AKR1A1 knockout cells had reduced cell viability, and the effect was aggravated by administering high dose palmitate. In addition, higher serum AKR1A1 concentrations in African Americans with T2D and preserved kidney function predicted slower decline rate in estimated glomerular filtration rate over time.

Conclusions: AKR1A1 appears to play a critical role in countering toxic effects of fatty acid metabolism and may prevent rapid decline of kidney function in African Americans with T2D.

查看原文本刊更多论文

血清AKR1A1水平预测非裔2型糖尿病患者eGFR下降率

背景：非裔美国人糖尿病肾病（DKD）的发病率高得不成比例。识别预测早期DKD进展的生物标志物对于在发生不可逆的组织学病变和显著降低肾功能之前提供保护性治疗至关重要。方法：我们通过敲除人肾近端小管细胞系中的AKR1A1，并通过测量2型糖尿病（T2D）非洲裔美国人血清AKR1A1浓度，来检测AKR1A1是否为早期DKD进展的标志。结果：AKR1A1基因敲除细胞可降低细胞活力，且高剂量棕榈酸盐可加重该作用。此外，患有T2D和保留肾功能的非裔美国人血清AKR1A1浓度较高，预测肾小球滤过率随时间的下降速度较慢。结论：AKR1A1似乎在对抗脂肪酸代谢的毒性作用中起关键作用，并可能阻止非裔美国人T2D患者肾功能的快速下降。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Kidney360 UROLOGY & NEPHROLOGY-

CiteScore

3.90

自引率

0.00%

发文量